Quinoline derivative and antibody soft tissue sarcoma combination therapy

Patent metadata

Field	Value
Publication number	US-12472173-B2
Application number	US-202017610212-A
Country	US
Kind code	B2
Filing date	May 11, 2020
Priority date	May 10, 2019
Publication date	Nov 18, 2025
Grant date	Nov 18, 2025

Abstract

The present invention belongs to the pharmaceutical field, and provides a quinoline derivative and antibody soft tissue sarcoma combination therapy, specifically relating to a use of a therapeutically effective amount of a quinoline derivative compound I or a pharmaceutically acceptable salt thereof in combination with at least one antibody drug in preparing a drug used for treating soft tissue sarcoma. The chemical name of the quinoline derivative compound I is 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine.

First claim

The invention claimed is:

1 . A method for treating a soft tissue sarcoma, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of toripalimab, wherein the soft tissue sarcoma is undifferentiated pleomorphic sarcoma:

2 . The method according to claim 1 , wherein the soft tissue sarcoma is a recurrent soft tissue sarcoma.

3 . The method according to claim 1 , wherein the soft tissue sarcoma is selected from the group consisting of a primary soft tissue sarcoma, a secondary soft tissue sarcoma, a soft tissue sarcoma that has progressed or recurred after being treated with at least one chemotherapy, a soft tissue sarcoma that is intolerant to chemotherapy, a soft tissue sarcoma that has not previously been systemically treated, and a soft tissue sarcoma that has not previously been treated with a tyrosine kinase inhibitor, an inhibitor for interaction between PD-1 receptor and its ligand PD-L1, or a cytotoxic T-lymphocyte antigen 4 inhibitor.

4 . The method according to claim 1 , wherein the subject has not previously been treated with systemic chemotherapy, or the subject has previously been treated with surgery, radiation therapy, induction chemotherapy, concurrent chemotherapy or adjuvant chemotherapy, or the subject has not previously been treated with systemic chemotherapy but has been treated with surgery, radiation therapy, induction chemotherapy, concurrent chemotherapy or adjuvant chemotherapy, or the subject has recurrence of disease progression after achieving complete response following surgery, radiation therapy, induction chemotherapy, concurrent chemotherapy or adjuvant chemotherapy, or the subject has failed to achieve complete response or partial response following surgery, radiation therapy, induction chemotherapy, concurrent chemotherapy or adjuvant chemotherapy, or cancer of the subject metastasized after the soft tissue sarcoma has been treated with surgery, radiation therapy, induction chemotherapy, concurrent chemotherapy or adjuvant chemotherapy.

5 . The method according to claim 1 , wherein toripalimab is administered once a week, once every 2 weeks, once every 3 weeks or once every 4 weeks; and the compound of formula I or the pharmaceutically acceptable salt thereof is administered at a dose of 6 mg, 8 mg, 10 mg or 12 mg once daily.

6 . The method according to claim 1 , comprising administering: (i) a pharmaceutical composition of the compound of formula I or the pharmaceutically acceptable salt thereof in a single dose of 6 mg, 8 mg, 10 mg or 12 mg, and (ii) a pharmaceutical composition of toripalimab in a single dose of 120-600 mg.

7 . The method according to claim 1 , wherein the compound of formula I or the pharmaceutically acceptable salt thereof is administered in an intermittent regimen of alternate treatment and interruption periods; wherein the ratio of the treatment period to the interruption period in days is 2:0.5-2:5, 2:0.5-2:3, 2:0.5-2:2, or 2:0.5-2:1; and wherein the intermittent regimen is in one of the following cycles: consecutively 2-week treatment and then 2-week interruption, consecutively 2-week treatment and then 1-week interruption, and consecutively 5-day treatment and then 2-day interruption.

8 . The method according to claim 1 , comprising administering: (i) a pharmaceutical composition of the compound of formula I or the pharmaceutically acceptable salt thereof in a single dose of 6 mg, 8 mg, 10 mg or 12 mg, and (ii) a pharmaceutical composition of toripalimab in a single dose of 240 mg.

9 . The method according to claim 1 , comprising administering: (i) a pharmaceutical composition of the compound of formula I or the pharmaceutically acceptable salt thereof in a single dose of 6 mg, 8 mg, 10 mg or 12 mg for 14 consecutive days, and (ii) a pharmaceutical composition of toripalimab at an amount of 240 mg in a single dose or multiple doses at first administration.

10 . The method according to claim 1 , wherein the pharmaceutically acceptable salt is an inorganic acid salt selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid, or the pharmaceutically acceptable salt is an organic acid salt selected from the group consisting of acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentane propionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, p-toluenesulfonic acid, 3-phenylpropionic acid, trimethylacetic acid, t-butylacetic acid, dodecyl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, and stearic acid.

11 . The method according to claim 1 , wherein the pharmaceutically acceptable salt is in the form of a dihydrochloride.

12 . The method according to claim 1 , wherein the soft tissue sarcoma is a metastatic soft tissue sarcoma.

13 . The method according to claim 1 , wherein the soft tissue sarcoma is a refractory soft tissue sarcoma.

14 . The method according to claim 1 , wherein the soft tissue sarcoma is an unresectable soft tissue sarcoma.

15 . The method according to claim 1 , wherein the soft tissue sarcoma is an advanced soft tissue sarcoma.

Assignees

• Chia Tai Tianqing Pharmaceutical Group Co Ltd

Inventors

• Wu Di
• Wang Huan

Classifications

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K16/2803

  against the immunoglobulin superfamily · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61K2039/54

  characterised by the route of administration · CPC title